The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 February 2026•

1 min read

TG Therapeutics Shares Surge on Robust BRIUMVI Sales and Strong 2026 Guidance

Key Facts

1U.S. BRIUMVI sales reached $594 million in 2025, a 90% year-over-year increase.

2The company guides for 2026 sales to be between $825 million and $850 million.

TG Therapeutics (TGTX) continues to demonstrate significant momentum as sales for its Multiple Sclerosis treatment, BRIUMVI, reached $594 million in the U.S. during 2025. This performance represents a substantial 90% year-over-year increase, highlighting rapid market adoption and robust demand. Looking ahead, the company has issued optimistic guidance for 2026, forecasting revenues between $825 million and $850 million. Investors are also focused on upcoming clinical milestones, including the Phase 3 ENHANCE study results and the development of a subcutaneous version of the drug. These advancements could further expand the company's competitive edge and market share. Consequently, analysts maintain a 'Strong Buy' rating based on this consistent growth trajectory and promising clinical pipeline.